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needed-to-treat of 5. The meta-analysis revealed a mean re-
sponse rate of 41.2% in the lithium group and 14.4% in the 
placebo group. One placebo-controlled trial in the continu-
ation treatment phase showed that responders to acute-
phase lithium augmentation should be maintained on the 
lithium-antidepressant combination for at least 12 months 
to prevent early relapses. Preliminary studies to assess ge-
netic influences on response probability to lithium augmen-
tation have suggested a predictive role of the –50T/C single 
nucleotide polymorphism of the GSK3  gene.  Conclusion: 
Augmentation of antidepressants with lithium is currently 
the best-evidenced augmentation therapy in the treatment 
of depressed patients who do not respond to antidepres-
sants.  Copyright © 2010 S. Karger AG, Basel 
 History of Lithium in Depression 
 Since the discovery of lithium in modern psychiatry 
in 1949, lithium has been mainly considered as a prophy-
lactic treatment for bipolar disorders and an acute treat-
ment of mania. Less attention has been given to lithium 
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 Abstract 
 Background: The late onset of therapeutic response and a 
relatively large proportion of nonresponders to antidepres-
sants remain major concerns in clinical practice. Therefore, 
there is a critical need for effective medication strategies 
that augment treatment with antidepressants.  Methods: To 
review the available evidence on the use of lithium as an 
augmentation strategy to treat depressive episodes.  Re-
sults: More than 30 open-label studies and 10 placebo-con-
trolled double-blind trials have demonstrated substantial 
efficacy of lithium augmentation in the acute treatment of 
depressive episodes. Most of these studies were performed 
in unipolar depression and included all major classes of an-
tidepressants, however mostly tricyclics. A meta-analysis in-
cluding 10 randomized placebo-controlled trials has provid-
ed evidence that lithium augmentation has a statistically sig-
nificant effect on the response rate compared to placebo 
with an odds ratio of 3.11, which corresponds to a number-
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and its potential value to treat and prevent acute depres-
sive episodes in unipolar depression  [1, 2] . As early as in 
the 1960s and 70s, the antidepressant effect of lithium 
was investigated by numerous studies. Although there is 
quite some evidence from these studies for an antidepres-
sive efficacy, lithium has never been used broadly as an 
antidepressant medication in unipolar and bipolar de-
pressed patients in clinical practice. The maintenance 
properties of lithium were investigated since the late 
1950s in both bipolar and unipolar affective illness. Many 
of these studies which focused on bipolar disease also had 
substantial data on the prophylactic effects of lithium in 
preventing the recurrence of unipolar depression. A re-
cent comprehensive review of these studies shows that 
lithium prevents the recurrence of unipolar depression 
 [1] . However, despite these findings the evidence failed to 
convince practitioners to use lithium to treat acute and 
prophylactic depressive disorders. This might be due to 
its relatively narrow therapeutic range of application and 
the necessity with lithium treatment to monitor lithium 
serum level regularly. The focus of this article is on an-
other effective application of lithium in the treatment of 
depressive disorders that emerged since the 1980s: lithi-
um augmentation of antidepressants.
 Augmentation Therapy in Depression 
 Although there are many drugs available for the treat-
ment of major depression, the overall treatment outcome 
of depressed patients is usually far from optimal. Regard-
less of the initial choice of antidepressant, about 30–50% 
of patients with a major depressive episode will not re-
spond sufficiently to adequately performed first-line 
treatment  [3] . Numerous treatment strategies have been 
described for use in antidepressant nonresponder and 
treatment-resistant depression  [4, 5] . Augmentation 
treatment strategies involve adding a second drug other 
than an antidepressant to the treatment regimen when no 
response or only partial response has been achieved, with 
the goal of enhancing treatment. Augmentation agents 
include lithium, thyroid hormones, atypical neurolep-
tics, anticonvulsants, stimulants and buspirone. One ad-
vantage of augmentation is that it eliminates the period 
of transition between 1 antidepressant to another and 
builds on the partial response. Consequently, when they 
work, augmentation strategies can have a rapid effect. 
Secondly, augmentation is of benefit for patients who 
have had some response and may be reluctant to risk los-
ing that improvement  [3] .
 Of these strategies, lithium augmentation therapy is 
among the best-studied ones  [6] . Lithium salts have been 
used to augment the efficacy of antidepressant medica-
tions for more than 25 years. The first study to test this 
hypothesis in patients with major depression was per-
formed by de Montigny et al.  [7] . They reported a dra-
matic response within 48 h to the addition of lithium in 
8 patients who had not responded to at least 3 weeks of 
treatment with tricyclic antidepressants. The efficacy of 
the combination and rapidity of response has led many 
clinical research groups to pursue study of this treatment 
intervention. Subsequent randomized controlled trials 
have confirmed de Montigny’s initial findings from 1981 
with more than 30 open-label and comparator studies 
including more than 500 depressed patients being pub-
lished  [8] . In these studies, the duration of antidepres-
sant before treatment ranged between 3 and 7 weeks with 
a mean of 4.5 weeks; the subsequent lithium augmenta-
tion therapy lasted between 2 days and 14 weeks with a 
mean duration of about 30 days. The antidepressants 
used in the trials included agents from different groups; 
among them were selective serotonin reuptake inhibitors 
(SSRIs), tri- and tetracyclic antidepressants, and mono-
amine oxidase inhibitors. The dosages of the antidepres-
sants used were not reported in all trials. The dosages of 
lithium carbonate ranged between 300 and 1,500 mg/
day. The response rates ranged widely between 100 and 
23.5% with a median of 56%; 10 of 17 open-label studies 
found response rates to lithium augmentation of 50% or 
more.
 A recent meta-analysis addressing the question pooled 
10 randomized, double-blind, placebo-controlled trials 
and included 269 mostly unipolar depressed patients  [9] . 
Lithium dosage, duration of treatment and other charac-
teristics of the studies are detailed in  table 1 . Lithium had 
a significant positive effect versus placebo with an odds 
ratio of 3.11, which corresponds to a number-needed-to-
treat of 5.  Table 1 shows the odds ratio for subjects re-
sponding to the treatment in each study by year of publi-
cation.
 However, 5 of the studies pooled did not show a sig-
nificant difference. Reasons for the negative findings may 
be low power  [10–12] , use of insufficient lithium doses 
 [13] , too short a duration of treatment  [10, 12] , and con-
cerns about the efficacy of lithium augmentation with 
noradrenergic antidepressants  [14, 15] . Previous studies 
had demonstrated that only doses of lithium carbonate 
higher than 600 mg/day and a duration of 7 days were 
useful in augmenting therapies  [16] .
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 Since the first meta-analysis  [16] , only 1 placebo-con-
trolled study has been published  [14] . As noted on the 
original meta-analysis published in 1999  [16] , a new neg-
ative study would have to include more than 2,500 pa-
tients per group to change the results of this pooling. 
However, it remains to be examined whether the response 
to lithium augmentation represents true augmentation 
resulting from synergistic effects or whether the response 
is simply owing to the antidepressant effect of lithium it-
self. Experimental studies supporting the former possi-
bility will be reviewed below. From the clinical point of 
view, arguments for a true augmentation effect derive 
from a controlled clinical trial showing that the antide-
pressant effects of lithium addition were significantly 
higher in amitriptyline-pretreated depression patients, 
compared with placebo-pretreated patients, who showed 
no improvement after a 3-week treatment  [17] . In sum-
mary, a randomized, double-blind study is warranted 
which investigates the effects of lithium alone and com-
pares them with the effects of lithium in combination 
with an antidepressant.
Table 1. Results of randomized, placebo-controlled lithium augmentation studies in depression
Study Subjects Antidepressant Lithium dosage (serum level) and
duration
Fixed effects:
odds ratioa (95% CI)
Response criteria;
response rates
Heninger et al.
[47], 1983
14 UP, 1 BP
12 F, 3 M
mean age 50 years
various TCAs
and tetracyclics
lithium carbonate 900–1,200 mg/day
(0.5–1.1 mEq/l)
12 days
23.57 (1.00–556.08) decrease of 2 or more
points on SCRS;
lithium: 62.5%
placebo: 0%
Kantor et al.
[10], 1986
7 UP
sex nr
mean age nr
various TCAs lithium carbonate 900 mg/day
48 h
3.00 (0.09–102.05) ≥40% decrease in
HAM-D score;
lithium: 25%
placebo: 0%
Zusky et al.
[11], 1988 
16 UP
13 F, 3 M
mean age 45 years
various TCAs
and MAOIs
lithium carbonate 300 mg/day first
week, 900 mg/day second week
14 days
1.80 (0.21–15.41) final HAM-D score ≤7; 
lithium: 38%
placebo: 25% 
Schöpf et al.
[30], 1989 
18 UP, 9 BP
19 F, 8 M
mean age 54 years
various
antidepressants
lithium carbonate 600–800 mg/day
(0.6–0.8 mEq/l)
7 days
27.00 (1.35–541.57) ≥50% decrease in HAM-D; 
lithium: 50%
placebo: 0%
Browne et al.
[12], 1990 
14 UP, 3 BP
10 F, 7 M
mean age 42 years
various TCAs
and tetracyclics
lithium carbonate 900 mg/day
48 h
3.00 (0.35–25.87) ≥50% decrease in HAM-D; 
lithium: 43%
placebo: 20%
Stein and 
Bernadt
[13], 1993 
34 UP
27 F, 7 M
mean age 47 years
various TCAs lithium carbonate 250 mg/day or
750 mg/day
21 days
0.50 (0.08–3.19) ≥50% decrease in HAM-D; 
lithium (250 mg): 18%
lithium (750 mg): 44% 
placebo: 22%
Joffe et al.
[21], 1993 
33 UP
18 F, 15 M
mean age 37 years
various TCAs lithium carbonate 900 mg/day
(>0.55 mEq/l)
14 days
4.88 (1.01–23.57) ≥50% decrease in HAM-D; 
lithium: 52%
placebo: 18.7%
Katona et al.
[48], 1995
61, polarity nr
35 F, 26 M
mean age 40 years
SSRI and TCA lithium 800 mg/day (0.6–1 mmol/l)
42 days
3.21 (1.09–9.48) ≥50% decrease in HAM-D; 
lithium: 53%
placebo: 25%
Baumann et al.
[49], 1996
23 UP, 1 BP
17 F, 7 M
mean age 41 years
SSRI
(citalopram)
lithium carbonate 800 mg/day
(0.5–0.8 mmol/l)
7 days
9.00 (1.27–63.89) ≥50% decrease in HAM-D; 
lithium: 58%
placebo: 14%
Nierenberg et al.
[14], 2003
35 UP
16 F, 19 M
mean age 38 years
TCA
(nortriptyline)
lithium carbonate 900 mg/day 0.58 (0.08–4.01) ≥50% decrease in HAM-D; 
lithium: 12.5%
placebo: 20%
UP = Unipolar; BP = bipolar; F = female; M = male; nr = not reported; MAOI = monoamine oxidase inhibitor; TCA = tricyclic antidepressant; HAM-
D = Hamilton Depression Rating Scale; SCRS = Short Clinical Rating Scale; CI = confidence interval.
a All studies: odds ratio 3.11 (1.80–5.37); data from meta-analysis.
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 Comparator Studies of Lithium Augmentation 
 Rarely have two augmentation strategies been com-
pared with each other under similar conditions, thus the 
relative magnitude of their effects is largely unknown. 
Among the comparators were electroconvulsive therapy 
 [18] , monoamine oxidase inhibitors  [19, 20] , thyroid hor-
mone  [21] , carbamazepine  [22, 23] , and high-dose SSRIs 
or tricyclic augmentation in SSRI users  [24] . In these 
studies, there has been no dramatic difference between 
lithium augmentation and any other strategy, although 
the varied quality of some studies – for example problems 
with trial duration, use of subtherapeutic doses of lithium 
and low power – should preclude drawing definite con-
clusions.
 Continuation Phase and Discontinuation Studies 
 One randomized controlled trial has examined the ef-
ficacy of lithium augmentation in the continuation treat-
ment phase of unipolar major depressive disorder  [25] . 
Twenty-nine patients with a refractory major depressive 
episode, single or recurrent, who had responded to acute 
lithium augmentation therapy during an open-label 6-
week study were randomized after a 2- to 4-week stabili-
zation period to a double-blind continuation treatment 
for another 4 months with either lithium (n = 14) or pla-
cebo (n = 15). The antidepressant was continued at the 
same dosage throughout the study. Seven of the 15 pa-
tients on placebo suffered from a relapse (5 depressive 
and 2 with a first manic episode) in the double-blind 
study phase, while no patients from the lithium group 
relapsed. Even more patients relapsed during the subse-
quent open-label 6-month phase after lithium was with-
drawn in the group previously receiving lithium  [26] . It 
was concluded that patients who respond to lithium aug-
mentation should be maintained on lithium augmenta-
tion for a minimum of 12 months or even longer  [26] .
 The effects of gradual discontinuation of lithium aug-
mentation therapy were assessed in a randomized, pla-
cebo-controlled discontinuation study in 12 elderly pa-
tients who had responded to lithium augmentation dur-
ing their most recent refractory unipolar depressive 
episode  [27] . Patients were randomized to receive contin-
ued lithium augmentation or matching placebo; 2 of 6 
patients in the lithium maintenance group had a recur-
rence of depression at 61 and 96 weeks, respectively, im-
mediately after a stressful life event. Similarly, 2 of 6 pa-
tients had a recurrence in the placebo group at 7 and 92 
weeks, respectively, without any apparent changes in life 
stresses. In a second, naturalistic discontinuation study 
in an elderly group of patients with major depressive dis-
order, about half of the patients relapsed following dis-
continuation of lithium augmentation  [28] . In a recent 
review article  [29] , it was concluded that there is a sig-
nificant risk of relapse in elderly patients whose lithium 
augmentation therapy for unipolar depression is discon-
tinued.
 Predictors of Response and Practical Use of Lithium 
Augmentation 
 A series of studies have investigated clinical and bio-
logical factors in lithium augmentation trials to allow 
outcome prediction  [17, 30–33] . Age and gender have con-
sistently been found  not to be associated with response. 
Some studies have observed that bipolar patients respond 
better than unipolar patients  [34] , but this has not been 
confirmed by others, likely because most patients en-
rolled in the augmentation studies suffered from unipo-
lar depression  [35] . An analysis of 71 depressed patients 
refractory to treatment with a tricyclic antidepressant 
demonstrated that patients with a more severe depressive 
syndrome were more likely to respond to lithium aug-
mentation  [33] .
 During the past decade, we have administered lithium 
augmentation in a fast titrating regimen in adults without 
major adverse events in depressed in- and outpatients. In 
adults (age up to 55 years; in elderly patients slower), lith-
ium carbonate is started on a daily dose of 450 mg (equiv-
alent to approximately 12 mmol/day), and the dose is in-
creased to 900 mg on the second day. This scheme leads 
to lithium serum levels of 0.5–0.7 mmol/l in most pa-
tients. The first dose adjustment can be performed after 
achieving a steady state, typically 5 days after the last 
change in dosing. Treatment of about 4 weeks allows as-
sessment of the patient’s response.
 Mechanisms of Lithium Augmentation 
 The underlying mechanisms of action involved in the 
potentiatory effect of lithium is still unclear and several 
hypotheses have been suggested such as activity and 
modulation on serotonin (5-HT) neurotransmission and 
endocrine systems  [36–38] . Initially, de Montigny and 
colleagues  [17, 39] postulated that a pharmacodynamic 
action mediated via the serotonergic systems may ac-
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count for the synergistic effect of lithium when added to 
a tricyclic antidepressant. From animal studies there is 
robust evidence that lithium augmentation increases 5-
HT neurotransmission, possibly through a synergistic 
action of lithium and the antidepressant on brain 5-HT 
pathways. Using microdialysis techniques in animals, 
addition of lithium to chronic citalopram therapy further 
elevated basal levels of 5-HT in the rat ventral hippocam-
pus  [40] . Further evidence for a ‘true’ augmentation effect 
derived from animal studies showed that, in contrast to 
lithium alone, the addition of lithium to antidepressant 
treatment with the SSRI, citalopram potentiated presyn-
aptic serotonergic function in rats  [41] . Specifically, some 
authors suggested that the effect of lithium on 5-HT neu-
rotransmission could be linked to a partial agonist activ-
ity on 5-HT1B autoreceptors or to a modulatory activity 
on these receptors  [38] . In a recent series of experiments, 
the effects of lithium were investigated in a battery of 
standard behavioral tests (e.g. Porsolt’s forced swim test, 
open-field test) that are considered animal models of de-
pression. In these studies, behavior was robustly affected 
dose dependently by chronic lithium treatment  [42, 43] 
suggesting lithium’s genuine antidepressant properties. 
Remarkably, these lithium-sensitive behaviors were also 
observed in mice lacking one copy of the gene encoding 
GSK3  , a well-established direct target of lithium  [42] .
 Pharmacogenetic approaches to assess genetic influ-
ences on response probability to lithium augmentation 
have also revealed some promising results. In a pilot 
study, the 5-HT transporter gene-linked polymorphic re-
gion (5-HTTLPR) allele variant’s effect on lithium aug-
mentation was analyzed in 50 antidepressant-nonrespon-
sive patients  [44] . Patients homozygous for the s allele of 
the 5-HTTLPR had a more favorable response compared 
with those heterozygous (hazard ratio = 6.9; p = 0.005) or 
homozygous for the l allele (hazard ratio = 4.5; p = 0.003). 
These findings support a differential effect of the 5-HT-
TLPR gene on treatment augmentation and the s/s geno-
type might predict an individual’s risk of antidepressant 
nonresponsiveness and sensitivity to augmentative drugs 
such as lithium.
 Another pharmacogenetic study investigated the as-
sociation of the GSK3  –50T/C single nucleotide poly-
morphism (SNP) and response to lithium augmentation 
in 81 unipolar depressed patients  [45] . Inhibition of 
GSK3  – an intracellular kinase, highly expressed in the 
brain – has been associated with neurotrophic and neu-
roprotective effects. Most interestingly, lithium is a direct 
and significant inhibitor of GSK3  . A –50T/C SNP local-
ized within the promoter region of the GSK3  gene has 
previously been shown to be associated with response to 
lithium prophylaxis in bipolar disorder  [46] . Similarly, 
carriers of the C allele of the –50T/C SNP showed a sig-
nificantly better response to lithium augmentation (haz-
ard ratio = 2.70, p = 0.007) with a mean remission rate of 
56.2% after 4 weeks compared to 31% in patients with the 
TT genotype  [45] . These results suggest a predictive role 
of the –50T/C SNP of the GSK3  gene for response to 
lithium augmentation treatment in depressed patients 
who do not respond sufficiently to monotherapy with an 
antidepressant. However, these promising data require 
confirmation in larger samples to be applicable in clinical 
routine care. Also, the functional relevance of the GSK3  
–50T/C SNP needs to be further investigated.
 Conclusion 
 Augmentation of antidepressants with lithium is the 
best-evidenced augmentation therapy in the treatment of 
depressed patients who do not respond to standard anti-
depressants.  The evidence reviewed here supports the 
recommendation of lithium augmentation as a first-line 
therapy for nonresponding and refractory depressed pa-
tients  [3, 4, 6] . In depressed patients who respond to lith-
ium augmentation, effective lithium doses should be con-
tinued in combination with the antidepressant for at least 
12 months after remission, in those patients with recur-
rent depression even longer  [25] . Unfortunately, this ef-
fective and generally well-tolerated strategy is widely un-
derutilized in clinical practice.
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